

DAFTAR PUSTAKA

- Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., Jeannin J. F., Coudert B. (2006). Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? *Br. J. Cancer* 94, 259–267 10.1038/sj.bjc.6602930
- Baskar R., Kuo A. Lee., Yeo R., and Kheng-Wei, Y., 2012, Cancer and Radiation Therapy: Current Advances and Future Directions, *Int. J. Med. Sci.* 2012, 9, 2012; 9(3):193-199. doi: 10.7150/ijms.3635
- BCAC, 2021, Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, et al: Breast cancer risk genes — Association analysis in more than 113,000 women. *N Engl J Med* 4;384 (5):428–439, 2021. doi: 10.1056/NEJMoa1913948
- Blake, L., PharmD, PhD, BCPS, Palumbo, A., PharmD, MPH, BCOP, Diaz, A., PharmD, BCOP; and Bubalo, J., PharmD, BCPS, BCOP, 2018, Anthracycline-Induced Cardiotoxicity in Adults, *Journal Of Hematology Oncology Pharmacy*, vol 8.
- Bowles, J. Erin, Aiello, R. Wellman, Heather, S. Feigelson, Adedayo A. Onitilo, Andrew, N. Freedman, Thomas Delate, Larry A. Allen, Larissa N., Katrina A. B. Goddard, Robert, L. Davis, Laurel A. Habel, Marianne Ulcickas Yood, Catherine Mccarty, David J. Magid, Edward H. Wagner, Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment, *jnci.oxfordjournals.org* DOI:10.1093/jnci/djs317
- Breast Cancer Expert Advisory Group (BCEAG), 2016, Clinical guidelines for the management of breast cancer, `\\ims.gov.uk\data\Users\GBEXPVD\EXPHOME25\PGoulding\Data\Desktop\guidelines- for-the-management-of-breast-cancer-v1.doc`
- Bruton, L., Lazo, J. S., and Parker, K. L., 2005, *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11th Edition, McGrawHill, Lange.
- Cahyawati, P. Nita., 2018, Imunoterapi Pada Kanker Payudara, *WICAKSANA Jurnal Lingkungan Dan Pembangunan*, vol. 2 No 1: 52-55
- Carrion C, Espinosa E, Herrero A, Garcia B (1995) "Possible vincristine-isoniazid interaction." *Ann Pharmacother*, 29, p. 201

- Chang, Wei-Ting, Chen, Po-Wei, Lin, Hui-Wen, Lin, Sheng-Hsiang and Li, Yi-Heng, 2021, Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan, *ESC Heart Failure* 2021; 8: 5149–5158 DOI: 10.1002/ehf2.13591
- Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., and Leeuwenburgh, 2002, Doxorubicin Treatment *in Vivo* Causes Cytochrome c Release and Cardiomyocyte Apoptosis, As Well As Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio, *Cancer Research*, 62:4592-4598.
- Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. (2000). Inhibitory Fc receptors modulate *in vivo* cytotoxicity against tumor targets. *Nat. Med.* 6, 443–446 10.1038/74704
- Csapo M, Lazar L. Chemotherapy-induced cardiotoxicity: pathophysiology and prevention. *Clujul Med.* 2014;87:135-142.
- Csige mre, Dora U., Zoltan S., Istvan L., Gyorgy Paragh, Mariann Harangi, and Sándor Somodi, Review Article, 2018, The Impact of Obesity on the Cardiovascular System, *Hindawi Journal of Diabetes Research* Volume 2018, Article ID 3407306, 12 pages <https://doi.org/10.1155/2018/3407306>
- Dean, L., Megan K., Victoria M. Pratt, Stuart A. Scott, Munir Pirmohamed, Bernard Esquivel, Brandi L. Kattman, Adriana J. Malheiro, 2015, Trastuzumab Therapy and ERBB2 Genotype, *Medical Genetics Summaries*, 2015 Aug 5 PMID: 28520362
- DIH., 2015, *Drug Information Handbook 17th Edition*, American Phamacist Association
- Dinas kesehatan provinsi DIY, 2019, *Profil Kesehatan Dinas Kesehatan Provinsi DIY 2018* : DinKes DIY
- Dipiro, J., Talbert, L.R., Yee, G.C., Matzke, G R., Wella, B.G., Possey, L., 2008, *Pharmacotherapy A Pathophysiologic Approach*, 7th Edition, Micc Grow Hill Medical, Washington Dc, 1026-1226.
- Dodion P, Akman SR, Tamburini JM, Riggs CE Jr, Colvin OM, Bachur NR (1986) "Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system." *J Pharmacol Exp Ther*, 237, p. 271-4
- Doroshov JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. *Proc Natl Acad Sci U S A.* 1986;83:4514–4518

Drug.com, 2024, Prescription Drug Information, Interactions & Side Effects, Terdapat di: https://www.drugs.com/drug_interactions.html [Diakses pada 2024]

Eaton, H., and Timm N. Kerstin, 2023, Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?, . *Cardio-Oncology* (2023) 9:22 <https://doi.org/10.1186/s40959-023-00172-3>

EMA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid

European Medicines Agency. 2010. Assessment Report For Herceptin. *European Medicines Agency Science Medicine Health*

Fawehinmi, Festus, 2020, *Pharmacokinetics Of Doxorubicin In Cancer Chemotherapy*, Department Of Physics And Astronomy University Of Lethbridge Lethbridge, Alberta, Canada

Gabani, M., Castañeda, D., Nguyen, Q. M., Choi, S. K., Chen, C., Mapara, A., et al. (2021). Association of cardiotoxicity with doxorubicin and trastuzumab: A double-edged sword in chemotherapy. *Cureus* 13 (9), e18194. doi:10.7759/cureus.18194

Gilbert CJ, Petros WP, Cavanaugh C, et al. (1995) "Influence of ondansetron (OND) on the pharmacokinetics (PK) of high dose cyclophosphamide (CPA) (Meeting abstract)." *Proc Annu Meet Am Soc Clin Oncol*, 14, a9311995

Glassman AH, Bigger JT Jr (2001) "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." *Am J Psychiatry*, 158, p. 1774-82

Globacan, 2020, Global Cancer Observatory. *Indonesia Cancer Fact Sheet. International Agency for Research on Cancer*. 2020. hal. 1–2

Goethals, I., De Winter, O., De Bondt, P., et al., 2002, The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. *Annals of Oncology*, 13, 1331–1339

Goodman, S. (2008, July). A dirty dozen: twelve p-value misconceptions. *In Seminars in hematology* (Vol. 45, No. 3, pp. 135-140). WB Saunders

Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non invasive imaging for detection of cardiovascular disease. *Eur Heart J*. 2014;35(10):612–23.

Hamirani, Ibrahim., Fanous, Christopher M., Kramer, Andrew Won., Michael Salerno, and Patrick Dillon, 2016, Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study, *Med Oncol.* 2016 July ; 33(7): 82. doi:10.1007/s12032-016-0797-x.

HCP, 2021, Herceptin Dosing, *Herceptin Prescribing Information*. Genentech, Inc. February 2021

Hequet, Q.H. Le, I. Moullet, E. Pauli, G. Salles, D. Espinouse, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults *J. Clin. Oncol.*, 22 (2004), pp. 1864-1871

Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., 2010, Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice, *Circulation*. 121 (5) :67583. doi: 10.1161/CIRCULATIONAHA.109.902221. PMC 2834271. PMID 20100968

Hudis, C. A. (2007). Trastuzumab — Mechanism of Action and Use in Clinical Practice. *New England Journal of Medicine*, 357(1), 39–51. doi:10.1056/nejmra043186

International agency for research on cancer., WHO, *Indonesia source: Globocan 2020*, diakses pada tanggal 21 April 2022

Jerusalem, G., Lancellotti, P. & Kim, S. B., 2019, HER2+ breast cancer treatment and cardiotoxicity: Monitoring and management. *Breast Cancer Res. Treat.* 177(2), 237–250 (2019)

Jung S, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, Fruit and vegetable intake and risk of breast cancer by hormone receptor status. *J Natl Cancer Inst.* 2013;105(3):219–36. <https://doi.org/10.1093/jnci/djs635>

Junttila TT, Akita RW, Parsons K, et al. Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. *Cancer Cell*. 2009;15:429–40

Kabore EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. (2019), Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. *PLoS Med* 16(12): e1002989. <https://doi.org/10.1371/journal.pmed.1002989>

Kemenkes RI, 2019, *Hari kanker sedunia 2019*, diakses pada tanggal 21 April 2022

- Kenchaiah S., Evans J. C., Levy D., et al. Obesity and the risk of heart failure. *New England Journal of Medicine*. 2002;347(5):305–313. doi: 10.1056/NEJMoa020245.
- Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarteet A, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. *Lancet Oncol*. 2013;14(10):1009–19. [https://doi.org/10.1016/S1470-2045\(13\)70301-2](https://doi.org/10.1016/S1470-2045(13)70301-2).
- Kibudde S, Mondo CK, Kibirige D, Walusansa V, Orem J. Anthracycline induced cardiotoxicity in adult cancer patients: a prospective cohort study from a specialized oncology treatment centre in Uganda. *Afr Health Sci*. 2019;19(1):1647–56.
- Klapper L. N., Waterman H., Sela M., Yarden Y. (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. *Cancer Res*. 60, 3384–3388
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA*. 2017;317(23):2402–16. <https://doi.org/10.1001/jama.2017.7112>.
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015 Jan;28(1):1-39.e14.
- Lemeshow, S., Hosmer Jr, D. W., Klar, J., & Lwanga, S. K. (1990). *Adequacy Of Sample Size In Health Studies*. New York: World Health Organization.
- Lin, Mengmeng., Weiping Xiong, Shiyuan Wang, Yingying Li , Chunying Hou , Chunyu Li and Guohui Li, 2022, The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment, *Front. Cardiovasc. Med.*, Volume 8 – 2021
- Linders A. Nicole, Itamar B. Dias, Teresa L. Fernández , Carlo G. Tocchetti, Nils Bomer 1 and Peter Van der Meer, 2024, A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging, *npj Aging* (2024) 10:9 ; <https://doi.org/10.1038/s41514-024-00135-7>

- Liu, F., Gu, L.-N., Shan, B.-E., Geng, C.-Z., & Sang, M.-X. (2016). Biomarkers for EMT and MET in breast cancer: An update. *Oncology Letters*, 12(6), 4869–4876. doi: 10.3892/ol.2016.5369
- Maifitrianti, Noorwati Sutandyo, Retnosari Andrajati, 2015, Faktor Yang Mempengaruhi Penurunan Fraksi Ejeksi Ventrikel Kiri Pada Pasien Kanker Yang Mendapatkan Kemoterapi Doksorubisin Di Rumah Sakit Kanker Dharmais, *Media Farmasi* Vol 12 No.2 September 2015 : 233-246
- Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA*. 2013;310(13):135368. <https://doi.org/10.1001/jama.2013.278040>
- Markey K.R., Mahipal A. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. *J. Oncol. Pharm. Pract.* 2016;22:552–555. doi: 10.1177/1078155215579303
- Merrill RM, Sloan A. Risk-adjusted female breast cancer incidence rates in the United States. *Cancer Epidemiol.* 2012;36(2):137–40. <https://doi.org/10.1016/j.canep.2011.08.004>.
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. 2004. Anthracyclins: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. *Pharmacol Rev.*, 56:185-228.
- NBCF, 2022, National Breast Cancer Foundation Inc, diakses pada tanggal 5 September 2022, <https://www.nationalbreastcancer.org/>
- NCCN, 2020, NCCN Guideline For Patient: Breast Cancer, [NCCN.org/patient](https://www.nccn.org/patient)
- Nuttall Q. Rank, MD, PhD, 2015, Body Mass Index Obesity, BMI, and Health: A Critical Review, *Nutr Today*. 2015;50(2):90Y97. DOI: 10.1097/NT.0000000000000100
- Perez, E. A. et al., 2008. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. *J. Clin. Oncol.* 26(8), 1231–1238 (2008).
- Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *J Clin Oncol.* 2007;25(25):3808–3815

- Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. *Eur J Cancer*. 2016;52:138–54. <https://doi.org/10.1016/j.ejca.2015.10.063>.
- Pizzino F, Vizzari G, Bomzer CA, Qamar R, Carerj S, Zito C, Khandheria BK. Diagnosis of chemotherapy-induced cardiotoxicity. *J Patient Cent Res Rev*. 2014;1:121-127. doi: 10.17294/2330-0698.1025
- Rasjidi, Imam, 2007, *Kemoterapi Kanker Ginekologi Dalam Praktek Sehari-Hari*, Jakarta : CV Sagungseto
- Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR (1982) "Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects." *Clin Pharmacol Ther*, 31, p. 263
- Rote, N. S. (2019). Cancer Biology. In *Pathophysiology: The biologic basis for disease in adults and children* (8th ed., pp. 346–378). St. Louis, MO: Elsevier.
- Santos, D.S. dos, R.C. dos Santos Goldenberg, 2018, Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy, Cardiotoxicity, *IntechOpen*
- Saputri, A., dan valentina, T.D., 2018, Gambaran Resiliensi Pada Perempuan Dengan Kanker Payudara. *Jurnal psikologi udayana edisi psikologi positif*
- Seferina, S. C. et al., 2016. Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice: A study of the Southeast Netherlands Breast Cancer Consortium. *Oncologist* 21(5), 555–562 (2016).
- Sengupta, Partho P. Md; Donald W. Northfelt, Md; Federico Gentile, Md; Jose L. Zamorano, Md; And Bijoy K. Khandheria, Md, 2008, Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads, *Mayo Clin Proc*. 2008;83(2):197-203, DOI:10.4065/83.2.197
- Shah, N. Ami, Otto M., Cynthia, H. Bartlett, Yuan L., Xin H., and Massimo C., 2020, Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents, *Oncologist*. 2020 Jun; 25(6): e900–e908. doi: 10.1634/theoncologist.2019-0729
- Shi, Y., Moon, M., Dawood, S., McManus, B. & Liu, P. P. Mechanisms and management of doxorubicin cardiotoxicity. *Herz* 36, 296–305 (2011).

- Siahaan, I.H., Tobing, T.C., Rosdiana, N. dan Lubis, B. (2007). Dampak kardi toksik obat kemoterapi golongan antrasiklin. *Sari Pediatri* 9 (2): 151-156.
- Slamon D.J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 344 (2001), pp. 783-792
- Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. *Life Sci*. 2021 Aug 01;278:119527
- Strasser F, Betticher DC, Suter TM (2001) "Trastuzumab and breast cancer." *N Engl J Med*, 345, p. 996
- Sugiyono, 2010, *Metode Penelitian Pendidikan Pendekatan Kuantitatif, kualitatif, dan R&D*. Bandung: Alfabeta
- Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. *Eur Heart J*. 2013;34:1102-1111.
- Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-life women with breast cancer. *J Card Fail* 2012;18:113-9.
- Vedam, K., Y. Nishijima, L.J. Druhan, M. Khan, N.I. Moldovan, J.L. Zweier, G, Ilangovan, 2010, Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice, *Am. J. Physiol. Heart Circ. Physiol.*, 298 (6) (2010), pp. H1832-H1841
- Wenningmann N., Knapp M., Ande A., Vaidya T., Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. *Mol. Pharmacol.* 96, 219–232 (2019).
- Wisman, Beta Agustia; Nasution, Sally Aman; and Panggabean, Marulam M., 2017, Cardiotoxicity Complication of Radiotherapy, *Jurnal Penyakit Dalam Indonesia*: Vol. 4: Iss. 4, Article 9. DOI: 10.7454/jpdi.v4i4.162
- Xu, M.F., P.L. Tang, Z.M. Qian, M. Ashraf, 2001, Effects by doxorubicin on the myocardium are mediated by oxygen free radicals, *Life Sci.*, 68 (8) (2001), pp. 889-901
- Yu, A. F. et al., 2019. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. *J. Am. Soc. Echocardiogr.* 32(4), 521–528 (2019).

Zager JS, Solorzano CC, Thomas E, Feig BW, Babiera GV. *Invasive Breast Cancer*. In: Feig BW, Berger DH, Fuhrman GM, editors. The 0D Anderson surgical oncology handbook. 4th ed. Houston: Lippincott Williams–Wilkins; 2006. p. 24.

Zhang S., Huang W. C., Li P., Guo H., Poh S. B., Brady S. W., Xiong Y., Tseng L. M., Li S. H., Ding Z., Sahin A. A., Esteva F. J., Hortobagyi G. N., Yu D. (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. *Nat. Med.* 17, 461–469 10.1038/nm.2551

Zhang, Li., Yan, Wang., Wenjing, Meng., Weipeng, Zhao., & Zhongsheng, Tong., 2022, Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer, *Scientific Reports* (2022) 12:14312 doi.org/10.1038/s41598-022-18342-1

Zhou, J., Zhong, Y., 2004, Breast Cancer immunotherapy. *Cellular and molecular immunology*. 1(4):245-255